Omnes Therapeutics
Ghent, Belgium· Est.
A Belgian AAV‑based gene‑therapy platform targeting rare metabolic diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
A Belgian AAV‑based gene‑therapy platform targeting rare metabolic diseases.
Rare Disease
Technology Platform
Proprietary AAV capsid engineering platform that creates vectors with enhanced peripheral tissue tropism and reduced immunogenicity.
Opportunities
A high unmet need in rare metabolic disorders combined with a differentiated AAV platform enables rapid pipeline expansion and attractive partnership or licensing opportunities.
Risk Factors
Technical challenges of AAV delivery, regulatory uncertainty for gene therapies, and competition from larger, more established gene‑therapy developers.
Competitive Landscape
Competes with Spark Therapeutics, UniQure, and other AAV‑focused firms, but differentiates through proprietary capsid engineering for peripheral tissue targeting and a focus on rare metabolic diseases.